This subproject will test the feasibility and efficacy of gene therapy for promoting neuronal survival and regeneration in the injured adult rat spinal cord either alone or in combination with a cellular transplantation intervention. Recombinant adeno-associated virus (rAAV) constructs will be employed to determine whether: (i) the efficacy of in vivo gene delivery to neurons can vary relative to post-injury times and the probability of either retrograde cell death or atrophy; (ii) in vivo gene delivery can promote rescue of embryonic and adult neuronal populations susceptible to post-axotomy cell death; and (iii) an effective delivery and expression of transgenes can be used to enhance axonal outgrowth from intraspinal grafts of fetal raphe tissue. Thus, the central hypothesis to be addressed is that either ex vivo and/or in vivo gene delivery can foster the synthesis and release of neurotrophic actors that in turn can serve to promote sparing of neuronal populations and stimulate or enhance axonal regeneration /sprouting following spinal cord injury (SCI) or peripheral nerve damage. Using sciatic nerve lumbar neuron pools (L4-L6) as a model, the efficacy of gene delivery will be compared at acute and chronic post- injury periods in Aim I. The selected post-injury times will relate to different epochs associated with initial retrograde (e.g., chromatolytic) responses and subsequent induced atrophy. Likewise, other experiments will examine the efficacy of gene delivery in two other intrinsic neuronal populations, rubrospinal and dorsal nucleus of Clarke, with contrasting cell survivals after SCI.
Aim II will determine whether a model population of neurons (i.e., motoneurons) can be rescued in both the adult spinal cord and grafts of fetal spinal cord (FSC) tissue by in vivo delivery of rAAVs expressing GDNF. The ability of transgene expression to rescue DNC neurons also will be examined. Lastly, Aim III will test the hypothesis that in vivo gene delivery, involving the expression of neurotrophins in conjunction with intraspinal grafts of fetal CNS tissue, can be used to augment host-graft connectivity by enhancing donor neuron-derived axonal sprouting and/or elongation. These experiments will investigate (i) whether the pattern of outgrowth exhibits any preferential disbursement relative to the distribution of transduced cells and (ii) to what extent the presence of NT-3 can promote growth of axons through a cellular milieu (e.g., astrogliotic scar) that can be inhibitory or non permissive to axonal regrowth. This subproject builds on a base of established expertise in SCI neurobiology/neuropathology, neurotransplantation, and AAV development to investigate fundamental issues related to gene transfer and repair of the damaged spinal cord.

Project Start
2000-12-01
Project End
2001-11-30
Budget Start
Budget End
Support Year
4
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Florida
Department
Type
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Dai, Xufeng; Han, Juanjuan; Qi, Yan et al. (2014) AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene replacement therapy rescues retinal degeneration in rd11 mice. Invest Ophthalmol Vis Sci 55:1724-34
Deng, Wen-Tao; Dinculescu, Astra; Li, Qiuhong et al. (2012) Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats. Invest Ophthalmol Vis Sci 53:1895-904
Wu, Ke; Li, Shoudong; Bodhinathan, Karthik et al. (2012) Enhanced expression of Pctk1, Tcf12 and Ccnd1 in hippocampus of rats: Impact on cognitive function, synaptic plasticity and pathology. Neurobiol Learn Mem 97:69-80
Petrs-Silva, Hilda; Dinculescu, Astra; Li, Qiuhong et al. (2011) Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 19:293-301
Pang, Ji-jing; Dai, Xufeng; Boye, Shannon E et al. (2011) Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther 19:234-42
Pang, J; Boye, S E; Lei, B et al. (2010) Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Ther 17:815-26
Gorbatyuk, Oleg S; Li, Shoudong; Nguyen, Frederic Nha et al. (2010) ?-Synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration. Mol Ther 18:1758-68
Gorbatyuk, Oleg S; Li, Shoudong; Nash, Kevin et al. (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 18:1450-7
Pang, Ji-Jing; Alexander, John; Lei, Bo et al. (2010) Achromatopsia as a potential candidate for gene therapy. Adv Exp Med Biol 664:639-46
Peden, Carmen S; Manfredsson, Fredric P; Reimsnider, Sharon K et al. (2009) Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Mol Ther 17:524-37

Showing the most recent 10 out of 68 publications